SCHEDULE 13D: Magnetar Funds Disclose 5.9% Stake in ProAssurance Corp Following Merger Agreement

Magnetar Financial and its affiliates have disclosed a 5.9% beneficial ownership stake in ProAssurance Corp, acquired primarily for merger arbitrage purposes following the announcement of its acquisition by The Doctors Company for $25.00 per share.

Summary

• Magnetar Financial LLC, Magnetar Capital Partners LP, Supernova Management LLC, and David J. Snyderman (collectively, the "Reporting Persons") have filed a Schedule 13D, disclosing beneficial ownership of 3,013,195 shares of ProAssurance Corp common stock.
• This stake represents approximately 5.90% of ProAssurance Corp's outstanding shares as of April 9, 2025, based on 51,069,793 shares outstanding reported by the Company on March 20, 2025.
• The shares were acquired on behalf of various funds managed by Magnetar, including PRA Master Fund, Systematic Master Fund, Relative Value Master Fund, and Managed Accounts.
• The aggregate amount of funds used for these purchases was $35,213,447.06, excluding commissions and other execution-related costs.
• The primary purpose of the acquisition was to receive the $25.00 per share cash merger consideration upon the consummation of ProAssurance Corp's merger with Jackson Acquisition Corporation, a wholly-owned subsidiary of The Doctors Company.
• The merger agreement was entered into on March 19, 2025, and approved by ProAssurance's Board of Directors.
• The Reporting Persons reserve the right to acquire or dispose of additional shares in the open market or privately negotiated transactions.

Sentiment

Score: 7

Explanation: The document is a factual disclosure of an investment position taken for merger arbitrage. The sentiment is positive from the perspective of the Reporting Persons, as they are executing a strategy based on an expected positive outcome (merger completion). It does not reflect on the underlying company's operational performance directly, but rather on the confidence in the merger closing.

Positives

• The acquisition of a significant stake by Magnetar indicates confidence in the announced merger between ProAssurance Corp and The Doctors Company.
• The Reporting Persons are positioned to realize a profit if the merger closes at the stated $25.00 per share consideration, given their average purchase price, which is a positive for their investment strategy.

Risks

• The primary risk for the Reporting Persons is that the announced merger may not be consummated, which would impact their investment strategy.
• The value of the shares could decline if the merger fails or is delayed, potentially leading to losses for the Reporting Persons.

Future Outlook

The Reporting Persons intend to hold the acquired shares to receive the $25.00 per share cash merger consideration upon the consummation of the merger between ProAssurance Corp and Jackson Acquisition Corporation. They retain flexibility to adjust their position by acquiring additional securities or disposing of existing shares.

Management Comments

• "The Reporting Persons acquired the 3,013,195 Shares reported herein on behalf of the Funds after the public announcement of the Merger Agreement... for purposes of receiving the merger consideration described below upon consummation of the Merger."
• "Each of the Reporting Persons reserves the right to acquire additional securities of the Company in the open market, in privately negotiated transactions, or otherwise, to dispose of all or a portion of the Shares and/or other securities reported in this Statement, or to change their intention with respect to any or all of the matters referred to in this Item 4."

Industry Context

This filing reflects a common merger arbitrage strategy where institutional investors acquire shares of a target company after a merger announcement, aiming to profit from the spread between the current market price and the announced merger consideration, assuming the deal closes. This is a typical event-driven investment strategy often seen in sectors undergoing consolidation, such as the insurance industry.

Comparison to Industry Standards

• The acquisition of a 5.9% stake by an institutional investor like Magnetar Financial is a significant position, consistent with the scale of investment typically undertaken for a merger arbitrage play.
• The strategy of buying shares after a merger announcement to capture the spread between the market price and the offer price is a standard practice in event-driven investing, commonly employed by hedge funds and specialized arbitrage firms.
• The stated merger consideration of $25.00 per share provides a clear target for the arbitrage strategy, which is a fundamental aspect of such investments.

Related Party Transactions

• The Reporting Persons (Magnetar Financial LLC, Magnetar Capital Partners LP, Supernova Management LLC, and David J. Snyderman) have entered into a joint filing agreement for this Schedule 13D, as permitted by Rule 13d-1(k)(1).

Stakeholder Impact

• Shareholders of ProAssurance Corp: The merger, if consummated, will result in them receiving $25.00 cash per share. The acquisition by Magnetar indicates institutional confidence in the merger's completion.
• The Doctors Company: The merger will result in ProAssurance becoming its wholly-owned subsidiary, expanding its operations.
• Magnetar Funds: The successful completion of the merger will allow the funds to realize the merger consideration, fulfilling their investment objective for these shares.

Next Steps

• Consummation of the merger between ProAssurance Corp and Jackson Acquisition Corporation, a subsidiary of The Doctors Company.
• Potential future acquisition or disposition of ProAssurance Corp shares by the Reporting Persons based on market conditions and merger progress.

Key Dates

Keywords

ProAssurance Corp, Magnetar Financial, Schedule 13D, Merger Agreement, The Doctors Company, Beneficial Ownership, Merger Arbitrage, Investment Adviser, Common Stock, SEC Filing